SC144
Based on 10 publication(s) in Google Scholar
SC144 is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 shows potent inhibition of gp130 ligand-triggered signaling. SC144 induces apoptosis in human ovarian cancer cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.48%
- CAS No.: 895158-95-9
- Formule: C16H11FN6O
- Masse moléculaire:322.30
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Orally Active Compound Library
HY-L061
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Posttranslational Modification Library
HY-L226
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
Publications Citing Use of MedChemExpress (MCE) SC144
More- Nat Med. 2024 Jun;30(6):1696-1710. [Abstract]
- Sci Adv. 2023 Jul 21;9(29):eadh0102. [Abstract]
- ACS Appl Mater Interfaces. 2024 Jun 19;16(24):30685-30702. [Abstract]
- Cell Rep. 2025 Aug 7;44(8):116114. [Abstract]
- J Invest Dermatol. 2024 Nov;144(11):2453-2464.e11. [Abstract]
- Biomater Adv. 2026 Jul:184:214814. [Abstract]
- Inflamm Res. 2023 Mar;72(3):493-507. [Abstract]
- Odontology. 2025 Jul;113(3):1081-1091. [Abstract]
- Biochem Biophys Res Commun. 2023 Dec 3:684:149068. [Abstract]
- bioRxiv. 2025 Nov 19.
Customer Validation & Images
-
IF
-
IHC
-
Histological Imaging/Staining
-
IF
-
WB
Activité biologique
|
IL6-beta |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.6 μM
Compound: SC144
|
Cytotoxicity against human HCT116 cells expressing p53 gene after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells expressing p53 gene after 72 hrs by MTT assay
|
[PMID: 17085054] |
| HCT-116 | IC50 |
0.9 μM
Compound: SC144
|
Cytotoxicity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 17085054] |
| HT-29 | IC50 |
0.9 μM
Compound: SC144
|
Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
|
[PMID: 17085054] |
| LNCaP | IC50 |
0.4 μM
Compound: SC144
|
Cytotoxicity against human LNCap cells after 72 hrs by MTT assay
Cytotoxicity against human LNCap cells after 72 hrs by MTT assay
|
[PMID: 17085054] |
| LNCaP | IC50 |
0.4 μM
Compound: 7
|
Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36971365] |
| MDA-MB-435 | IC50 |
0.4 μM
Compound: 7
|
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36971365] |
| MDA-MB-435 | IC50 |
4 μM
Compound: SC144
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
|
[PMID: 17085054] |
SC144 inhibits cell growth in a panel of human ovarian cancer cell lines with IC50s in a submicromolar range (IC50=OVCAR-8, OVCAR-5, OVCAR-3= 0.72, 0.49, 0.95 μM)[1].
The potency of SC144 toward NCI/ADR-RES (Paclitaxel- and Doxorubicin-resistant, IC50=0.43 μM) and HEY (Cisplatin-resistant, IC50=0.88 μM) suggests an ability to overcome drug resistance in ovarian cancer[1].
SC144 (2 μM; 24 hours) causes significantly more apoptosis in OVCAR-8 and Caov-3 than normal kidney epithelial and normal endometrial cells[1].
SC144 (0.5-2 μM; 0-6 hours) substantially increases the phosphorylation of gp130 (S782) in both OVCAR-8 and Caov-3 cells in a time- and dose-dependent manner[1].
SC144 is cytotoxic to ovarian cancer cells via a mechanism involving the inhibition of gp130 activity, leading to the inactivation of Akt and Stat3 as well as the suppression of Stat3-regulated gene expression. As are result, SC144 treatment eventually causes cell-cycle arrest, anti-angiogenesis, and apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:OVCAR-8 and Caov-3 cells
-
Concentration:2 μM
-
Incubation Time:24 hours
-
Result:Significantly caused cell death in OVCAR-8 and Caov-3 cells.
-
Cell Line:OVCAR-8, Caov-3 cells
-
Concentration:0.5-2 μM
-
Incubation Time:0-6 hours
-
Result:Substantially increased the phosphorylation of gp130 (S782) in both OVCAR-8 and Caov-3 cellsin a time- and dose-dependent manner.
SC144 (100 mg/kg;p.o.; daily for 35 days) treatment shows the average tumor volume in mice 82% smaller than that in the control group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic mice (human ovarian cancer xenograft)[1]
-
Dosage:10 mg/kg
-
Administration:I.p; daily for 58 days
-
Result:Significantly inhibited tumor growth by about 73%.
Chemical Information
-
CAS No. 895158-95-9
-
Appearance Solid
-
Masse moléculaire 322.30
-
Formule C16H11FN6O
-
Color Light yellow to yellow
-
SMILES
O=C(C1=NC=CN=C1)NNC2=NC3=C(N4C2=CC=C4)C=CC(F)=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Med
Multiomic analyses uncover immunological signatures in acute and chronic coronary syndromes. [Abstract]2024 Jun;30(6):1696-1710. PMID: 38773340 -
Sci Adv
The astrocytic TRPA1 channel mediates an intrinsic protective response to vascular cognitive impairment via LIF production. [Abstract]2023 Jul 21;9(29):eadh0102. PMID: 37478173
SC144 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jul 21;9(29):eadh0102. [Abstract]
SC144 (10 mg/kg). Representative image of myelin staining of the corpus callosum on postoperative day 14.
-
ACS Appl Mater Interfaces
Mg-Cross-Linked Alginate Hydrogel Induces BMSC/Macrophage Crosstalk to Enhance Bone Tissue Regeneration via Dual Promotion of the Ligand-Receptor Pairing of the OSM/miR-370-3p-gp130 Signaling Pathway. [Abstract]2024 Jun 19;16(24):30685-30702. PMID: 38859670 -
Cell Rep
2025 Aug 7;44(8):116114. PMID: 40782349
SC144 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Aug 7;44(8):116114. [Abstract]
Representative IF staining of pSTAT3 (red) and PDGFRA (green) in Il4rafl/fl and Il4raΔPdgfra with vehicle or SC144 (10 mg/kg) in d7 MC903, quantified at right.
-
J Invest Dermatol
E3 Ubiquitin Ligase NEDD4L Negatively Regulates Skin Tumorigenesis by Inhibiting IL-6/GP130 Signaling Pathway. [Abstract]2024 Nov;144(11):2453-2464.e11. PMID: 38580105
SC144 purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2024 Nov;144(11):2453-2464.e11. [Abstract]
Quantitative standardized immunohistochemical (IHC) analysis showed that keratinocyte-specific knockout of Nedd4l significantly promoted the expression of Ki-67, p-STAT3 (Y705) and cyclin D1 in tumor tissues; however, administration of SC144 (10 mg/kg) completely eliminated these effects.
SC144 purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2024 Nov;144(11):2453-2464.e11. [Abstract]
Representative images for H&E staining of papilloma and cSCC tissues in WT and Nedd4l-cKO mice treated with or without SC144 (10 mg/kg). Arrows indicate keratin pearl.
-
Biomater Adv
Optimal Se content on P/G-EGCG@Se nanofibers reverses muscle-derived IL-6- induced osteogenesis depression. [Abstract]2026 Jul:184:214814. PMID: 41832820 -
Inflamm Res
Inhibition of gp130 alleviates LPS-induced lung injury by attenuating apoptosis and inflammation through JAK1/STAT3 signaling pathway. [Abstract]2023 Mar;72(3):493-507. PMID: 36617342
SC144 purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2023 Mar;72(3):493-507. [Abstract]
SC144 (20 mg/kg; dissolved in DMSO; i.p.; single) significantly inhibits the expression of gp130 in mouse lung tissue.
SC144 purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2023 Mar;72(3):493-507. [Abstract]
RT-PCR was used to analyze the relative expression levels of IL-6 mRNA (20 mg/kg) in mouse lung tissue after LPS and SC144 treatment.
-
Odontology
Transcriptional regulation of human follicular dendritic cell-secreted protein gene by interleukin-6. [Abstract]2025 Jul;113(3):1081-1091. PMID: 39776305 -
Biochem Biophys Res Commun
2023 Dec 3:684:149068. PMID: 37866240 -
Solvant et solubilité
DMSO : 16.67 mg/mL (51.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1027 mL | 15.5135 mL | 31.0270 mL | 77.5675 mL |
| 5 mM | 0.6205 mL | 3.1027 mL | 6.2054 mL | 15.5135 mL | |
| 10 mM | 0.3103 mL | 1.5513 mL | 3.1027 mL | 7.7567 mL | |
| 15 mM | 0.2068 mL | 1.0342 mL | 2.0685 mL | 5.1712 mL | |
| 20 mM | 0.1551 mL | 0.7757 mL | 1.5513 mL | 3.8784 mL | |
| 25 mM | 0.1241 mL | 0.6205 mL | 1.2411 mL | 3.1027 mL | |
| 30 mM | 0.1034 mL | 0.5171 mL | 1.0342 mL | 2.5856 mL | |
| 40 mM | 0.0776 mL | 0.3878 mL | 0.7757 mL | 1.9392 mL | |
| 50 mM | 0.0621 mL | 0.3103 mL | 0.6205 mL | 1.5513 mL |
SC144 Related Classifications
HY-15614 Related Classifications
Powered by Bioz